<DOC>
	<DOC>NCT01785108</DOC>
	<brief_summary>The objectives of this study is to - evaluate the safety and influence of treatment with GAD-Alum (Diamyd) combined with Vitamin D and Ibuprofen on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes - evaluate how the above mentioned treatments influence the immune system of the subjects and interact with any viral infections - evaluate the safety and influence of treatment with double dose of GAD-Alum (Diamyd) plus Vitamin D on the immune system, viral infections, and on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes</brief_summary>
	<brief_title>DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Main Male and female patients between 10 and 18 years of age Insulin dependent Type 1 Diabetes mellitus diagnosed within the previous 4 months at time of screening Fasting Cpeptide level at time of screening above or equal to 0.12 nmol/L Elevated GAD65 antibodies (GADA) at time of screening Main Treatment with immunosuppressants, continuous antiinflammatory drug, Vitamin D or any antidiabetic medications other than insulin A history of certain diseases or conditions (e.g. anemia, HIV, epilepsy, head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse etc) Treatment with any vaccine within 4 months prior to first planned administration of GADAlum/placebo or planned treatment with vaccine up to 4 months after the last injections with GADAlum/Placebo, including influenza vaccines Participation in other clinical trials with a new chemical entity within the previous 3 months Pregnancy or planned pregnancy within 1 year after the last GADAlum/placebo dose Presence of associated serious disease or condition which in the opinion of the investigator makes the patient noneligible for the study</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diamyd</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Juvenile Diabetes</keyword>
	<keyword>Diabetes type 1</keyword>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Insulin dependent Diabetes</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
	<keyword>rhGAD65</keyword>
	<keyword>GAD</keyword>
	<keyword>GAD65</keyword>
	<keyword>GAD-alum</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus, Type 1</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Ibuprofen</keyword>
</DOC>